Famotidine/ibuprofen - Horizon Pharma

Drug Profile

Famotidine/ibuprofen - Horizon Pharma

Alternative Names: Duexa; Duexis; HZT-501; Ibuprofen/famotidine

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Horizon Therapeutics
  • Developer Horizon Pharma; Horizon Pharma USA
  • Class Antiulcers; Gastric antisecretories; Nonsteroidal anti-inflammatories; Phenylpropionates; Thiazoles
  • Mechanism of Action Cyclooxygenase inhibitors; Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain; NSAID-induced ulcer; Osteoarthritis; Rheumatoid arthritis
  • Discontinued Ankylosing spondylitis

Most Recent Events

  • 27 Mar 2015 Famotidine/ibuprofen is still registered for prevention of Ankylosing spondylitis, NSAID-induced ulcer, Osteoarthritis and Rheumatoid arthritis in United Kingdom
  • 07 Mar 2013 Registered for Ankylosing spondylitis in United Kingdom (PO)
  • 07 Mar 2013 Registered for NSAID-induced ulcer in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top